{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:59:50Z","timestamp":1790823590391,"version":"4.1.0"},"reference-count":41,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Novartis Farma Italy","doi-asserted-by":"publisher","award":["PI21\/00054"],"award-info":[{"award-number":["PI21\/00054"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Patients with chronic inflammatory arthritis have a higher cardiovascular (CV) risk than the general population. Traditional CV risk factors are clearly implicated, while the impact of metabolic syndrome (MetS) is less defined. The aim of this study was to compare MetS prevalence and impact on the CV risk in psoriatic arthritis (PsA) versus rheumatoid arthritis (RA). A retrospective analysis of real-world data of PsA and RA patients referred to a rheumatology clinic was conducted. The following data were extracted and compared: demographic data; clinical data; presence of traditional CV risk factors and MetS. Univariate and multivariate models were used to compare the impact of MetS and its components in patients with PsA versus RA. Overall, 170 patients were included (PsA: 78; RA; 92). The two groups differed significantly in mean age, disease duration, and presence of MetS, while other variables were comparable. Univariate and multivariate analysis identified distinct predictors of MetS in PsA (hypertension) and RA (dyslipidemia). The history of CV events was similar in the two groups. Predictors of CV events were MetS and most of its components in PsA, while dyslipidemia was the strongest predictor in RA. These associations were stronger in PsA than in RA. In conclusion, the impact of MetS and its components is different in PsA and RA. The association of these risk factors with CV events is stronger in PsA than in RA. This suggests the implication of different mechanisms, which may require distinct strategies for the prevention of CV events in PsA and RA.<\/jats:p>","DOI":"10.3390\/jcm12155031","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T10:00:15Z","timestamp":1690797615000},"page":"5031","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Metabolic Syndrome and Its Components Have a Different Presentation and Impact as Cardiovascular Risk Factors in Psoriatic and Rheumatoid Arthritis"],"prefix":"10.3390","volume":"12","author":[{"given":"Fabiola","family":"Atzeni","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"La Corte","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Giallanza","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Galloway","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, Kings College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-5102","authenticated-orcid":false,"given":"Javier","family":"Rodr\u00edguez-Carrio","sequence":"additional","affiliation":[{"name":"Area of Immunology, Department of Functional Biology, Faculty of Medicine, University of Oviedo, 33006 Oviedo, Spain"},{"name":"Instituto de Investigac\u00edon Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.39098","article-title":"Disease activity in rheumatoid arthritis and the risk of CV events","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major CV events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.15420\/ecr.2020.44","article-title":"Atherosclerotic CV Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment","volume":"16","author":"Kerola","year":"2021","journal-title":"Eur. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Dijkshoorn, B., Raadsen, R., and Nurmohamed, M.T. (2022). CV Disease Risk in Rheumatoid Arthritis Anno 2022. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102704"},{"key":"ref_5","first-page":"547","article-title":"2016 European guidelines on CV disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on CV Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts. Developed with the special contribution of the European Association for CV Prevention & Rehabilitation","volume":"18","author":"Piepoli","year":"2017","journal-title":"G. Ital. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chen, J., Norling, L.V., and Cooper, D. (2021). Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. Cells, 10.","DOI":"10.3390\/cells10040881"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of CV Morbidity in Patients with Psoriatic Arthritis: A Meta-Analysis of Observational Studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"735150","DOI":"10.3389\/fmed.2021.735150","article-title":"Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?","volume":"8","author":"Atzeni","year":"2021","journal-title":"Front. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"785719","DOI":"10.3389\/fmed.2022.785719","article-title":"Increased CV Risk in Psoriatic Arthritis: Results from a Case-Control Monocentric Study","volume":"9","author":"Koch","year":"2022","journal-title":"Front. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2011.75","article-title":"Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE","volume":"7","author":"Symmons","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1258\/000456307780480963","article-title":"Metabolic syndrome and CV disease","volume":"44","author":"Qiao","year":"2007","journal-title":"Ann. Clin. Biochem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/acr.23171","article-title":"Incidence and Prevalence of CV Risk Factors Among Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis","volume":"69","author":"Radner","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/acr.23094","article-title":"Incidence and Management of CV Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study","volume":"69","author":"Jafri","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/1756-185X.14147","article-title":"Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis","volume":"24","author":"Loganathan","year":"2021","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1759720x21998279","DOI":"10.1177\/1759720X21998279","article-title":"Psoriatic arthritis and the association with cardiometabolic disease: A narrative review","volume":"13","author":"Karmacharya","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for CV disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: An American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.semarthrit.2014.12.002","article-title":"Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project","volume":"44","author":"Llorca","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#","article-title":"High incidence of CV events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors","volume":"44","author":"Williams","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1002\/art.21397","article-title":"Relative contribution of CV risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis","volume":"52","author":"Freeman","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1136\/annrheumdis-2013-205058","article-title":"Systemic inflammation and CV risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis","volume":"74","author":"Polak","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","article-title":"Impact of risk factors associated with CV outcomes in patients with rheumatoid arthritis","volume":"77","author":"Crowson","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1097\/RHU.0000000000001738","article-title":"Prevalence of Metabolic Syndrome in Psoriatic Arthritis: Systematic Literature Review and Results from the CARMA Cohort","volume":"28","author":"Loza","year":"2022","journal-title":"J. Clin. Rheumatol."},{"key":"ref_26","first-page":"197","article-title":"Personalizing metabolic disease therapies","volume":"25","author":"Stower","year":"2019","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"E2271","DOI":"10.1210\/jc.2012-1996","article-title":"Circulating miRNA profiles in patients with metabolic syndrome","volume":"97","author":"Karolina","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1210\/clinem\/dgab922","article-title":"Metabolic Profiling of Obesity with and Without the Metabolic Syndrome: A Multisample Evaluation","volume":"107","author":"Lind","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_29","first-page":"624","article-title":"Metabolic and Inflammatory Profiles of Biomarkers in Obesity, Metabolic Syndrome, and Diabetes in a Mediterranean Population. DARIOS Inflammatory Study; Metabolic and inflammatory profiles of biomarkers in obesity, metabolic syndrome, and diabetes in a Mediterranean population. DARIOS Inflammatory study","volume":"67","author":"Penafiel","year":"2014","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/ard.2008.101964","article-title":"Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: A challenge to conventional CV risk actions","volume":"68","author":"Choy","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","article-title":"Changes in lipid levels with inflammation and therapy in RA: A maturing paradigm","volume":"9","author":"Robertson","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00296-004-0438-0","article-title":"Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: Serum levels and relationship to inflammation","volume":"25","author":"Polat","year":"2005","journal-title":"Rheumatol. Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/art.21976","article-title":"Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"54","author":"McMahon","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: The impact of serum lipid measures and systemic inflammation on the risk of CV disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1093\/rheumatology\/keaa346","article-title":"The HDL dysfunction gains momentum: Is it time for a new approach in rheumatic diseases?","volume":"59","author":"Suarez","year":"2020","journal-title":"Rheumatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: Lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5152\/eurjrheum.2019.19029","article-title":"Are there any differences among psoriasis, psoriatic arthritis and rheumatoid arthritis in terms of metabolic syndrome and CV risk factors?","volume":"6","author":"Cefle","year":"2019","journal-title":"Eur. J. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.semarthrit.2018.03.005","article-title":"CV risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis","volume":"48","author":"Cooksey","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/annrheumdis-2015-207980","article-title":"Incidence and predictors for cardiovascular events in patients with psoriatic arthritis","volume":"75","author":"Eder","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2174\/1381612824666180123102632","article-title":"Inflammatory Arthritis and Heart Disease","volume":"24","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/rheumatology\/kes243","article-title":"Traditional CV risk factors, inflammation and CV risk in rheumatoid arthritis","volume":"52","author":"Liao","year":"2013","journal-title":"Rheumatology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/15\/5031\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:22:59Z","timestamp":1760127779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/15\/5031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":41,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["jcm12155031"],"URL":"https:\/\/doi.org\/10.3390\/jcm12155031","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]}}}